TDP2 antibody

Catalog No. ABIN2704362

Product Details anti-TDP2 Antibody

Target: TDP2 (tyrosyl-DNA phosphodiesterase 2 (TDP2))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This TDP2 antibody is un-conjugated

Application: Western Blotting (WB)

Characteristics: EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5'- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease. Emerging data suggest that EAPII is a multi-functional protein: it repairs enzyme (topoisomerase)-mediated DNA damage by removing phosphotyrosine from DNA adducts, involves in multiple signal transduction pathways such as TNF-TNFR, TGFβ and MAPK, and responsive to immune defense including inflammatory response, viral infection and DNA toxins (chemo or radiation therapy). EAPII predominantly localizes to the nucleus, but based on pathological conditions it also localizes in both cytoplasm and nucleus.

Purification: Purified

Purity: >95 %

Grade: GMP Grade

Immunogen: Recombinant full length protein

Clone: 42c

Isotype: IgG2b kappa

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: PBS pH 7.2, 0.1 % (w/v) BSA, 0.09 % (w/v) sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Target Details for TDP2

Target: TDP2 (tyrosyl-DNA phosphodiesterase 2 (TDP2))

Alternative Name: EAPII (TDP2 Products)

Synonyms: AD022 antibody, EAP2 antibody, EAPII antibody, TTRAP antibody, dJ30M3.3 antibody, hTDP2 antibody, ad022 antibody, eap2 antibody, ttrap antibody, D13Ertd656e antibody, Ttrap antibody, tdp2 antibody, ttrapl antibody, tyrosyl-DNA phosphodiesterase 2 antibody, tyrosyl-DNA phosphodiesterase 2 S homeolog antibody, tyrosyl-DNA phosphodiesterase 2b antibody, TDP2 antibody, tdp2.S antibody, Tdp2 antibody, tdp2b antibody

Background: EAPII (also called TTRAP, TDP2) originally was identified as an interacting partner of oncogene ETS1, a founding member of ets transcription factor, and the cytoplasmic domain of CD40, a member of the tumor necrosis factor (TNF) receptor family. EAPII significantly represses ETS1 transcriptional activity and the synergistic transactivation by ETS1 and AP-1 or by ETS1 and NFκB. EAPII/TTRAP also inhibits the transcriptional activation of NFB induced by CD40 or phorbol 12-myristate 13-acetate (PMA). Recently this protein was also proven to be the first 5'- tyrosyl-DNA phosphodiesterase. EAPII has been demonstrated to have promiscuous protein associations, broad responsiveness to various extracellular signals, and pleiotropic functions in the development of human diseases including cancer and neurodegenerative disease. Emerging data suggest that EAPII is a multi-functional protein: it repairs enzyme (topoisomerase)-mediated DNA damage by removing phosphotyrosine from DNA adducts, involves in multiple signal transduction pathways such as TNF-TNFR, TGFβ and MAPK, and responsive to immune defense including inflammatory response, viral infection and DNA toxins (chemo or radiation therapy). EAPII predominantly localizes to the nucleus, but based on pathological conditions it also localizes in both cytoplasm and nucleus.

NCBI Accession: NM_016614

UniProt: O95551